High Dimensional Analysis of Immune Cells in Pediatric Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2-18
SponsorSeoul National University Hospital
About this trial
The purpose of this study is to characterize immune cells using single-cell transcriptomic analysis in pediatric patients aged 2 to 18 years undergoing general anesthesia who are expected to receive Rocuronium, a non-depolarizing neuromuscular blocking agent, in the event of an allergic reaction.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Pediatric patients between the ages of 2 and 18 undergoing general anesthesia and surgery using the neuromuscular blocker, rocuronium.
Disqualifiers
Patients who have received immunomodulators, immunosuppressants, etc.
Patients with autoimmune diseases (rheumatoid arthritis, lupus, Behcet's disease, etc.)
Patients who regularly take, or have taken within 4 weeks, medications that may affect the immune system (oral steroids, anti-inflammatories, etc.)
Other cases where the Principal Investigator determines that it is difficult to conduct the study.
Trial population
Pediatric patients between the ages of 2 and 18 undergoing general anesthesia using the rocuronium.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Transcriptomic profile analysis of the T lymphocytes by RNA sequencing
Blood sample from the patients when patient shows allergic reaction after administration of rocuronium
Time frame
until end of surgery (usually up to 12 hours from the first dose of rocuronium)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov